DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

Post-LOE

dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate

PharmaIN

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Sep 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate) by PharmaIN is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder (adhd) in patients 13 years, older limitations of use pediatric patients 12 years, younger experienced higher plasma exposure than patients 13 years and 9 more indications. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.

Indications (12)

Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years older Limitations of Use Pediatric patients 12 years

Worked on DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.